| Metric | Value ($ M) | vs Q2 FY26 |
|---|---|---|
| Revenue | 1.49 | 10.8% |
| Total Income | 1.49 | 10.8% |
| Expenditure | 10.21 | 66.3% |
| PBT | -9.03 | 66.4% |
| Net Profit | -8.92 | 66.5% |
| OPM | — | |
| NPM | — | |
| EPS | -0.08 | 70.4% |
Citius Oncology Reports Q3 FY26 Financial Results and Provides Business Update
15 Aug 2026 · 15 Aug, 2:18 am
Summary
Citius Oncology reported revenues of $1.5 million for the third quarter of fiscal 2026, marking a significant increase from zero revenue in the prior year period, and $7.1 million for the first nine months of fiscal 2026. Institutional demand for LYMPHIR is accelerating, with vial orders increasing 31% sequentially in the quarter and 44 institutions having ordered the product. Despite the revenue growth, the company reported a net loss of $8.9 million for the quarter. Management expressed confidence in continued institutional demand translating into increased wholesale orders and revenue, citing a positive trajectory of formulary approvals and adoption.
Key Highlights
- 1
Citius Oncology reported revenues of $1.5 million for the three months ended June 30, 2026, compared to no revenue in the prior year quarter.
- 2
For the first nine months of fiscal 2026, revenues reached $7.1 million, a significant increase from zero revenue in the comparable prior-year period.
- 3
Institutional vial orders for LYMPHIR grew 31% sequentially in Q3 FY26, with 926 vials ordered compared to 708 in the prior quarter.
- 4
LYMPHIR has been ordered by 44 institutions since its launch.
- 5
The company reported a net loss of $8.9 million, or $(0.08) per share, for the three months ended June 30, 2026.
- 6
Cash and cash equivalents stood at $16.6 million as of June 30, 2026.
Management Comments
Leonard Mazur
Institutional demand (LYMPHIR vials ordered by prescribing centers from wholesalers) is accelerating. Institutional vial orders grew 31% sequentially, from 708 in the quarter ended March 31, 2026 to 926 in the quarter ended June 30, 2026. In July, institutions ordered 383 vials from wholesalers, the largest order month to date, reflecting a 25% increase over the prior quarter’s monthly average order. Currently, 44 institutions have prescribed and ordered LYMPHIR. We expect continued institutional demand to drive new wholesaler orders. The Company recognizes revenue when wholesaler orders are fulfilled. Consequently, net revenue for any period reflects actual wholesaler orders fulfilled. In July, we began to see growth in institutional demand translate into increased wholesale orders and associated revenue. The positive trajectory of formulary approvals, institutional adoption, and unit demand gives us confidence in a robust remainder of the fiscal year. We generated initial momentum with a lean internal team, maintaining healthy product margins and securing broad market access. In August, our full 29-person-strong commercial and medical affairs organizations expanded to nationwide coverage. The teams are now positioned to accelerate commercial execution and support broader adoption by leveraging the comprehensive, scalable infrastructure already established for LYMPHIR, including patient hub services, marketing and reimbursement support. Citius Oncology is now well positioned to broaden engagement with treatment centers, targeting formulary inclusion at 100 priority institutions by year-end and first-in-class support for health care providers. At the same time, we continue to advance LYMPHIR’s longer-term value proposition through investigator-initiated studies exploring its potential in combination regimens beyond CTCL. Overall, the launch is moving in the right direction: more institutions are ordering LYMPHIR, vial demand is increasing, and our commercial footprint is expanding. We believe the underlying increasing demand trends provide a strong basis for the remainder of fiscal 2026.
Informational and educational content only. Not investment advice.